Physician Wealth Advisors Inc. Has $271,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Physician Wealth Advisors Inc. increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 12.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,171 shares of the medical instruments supplier’s stock after buying an additional 134 shares during the period. Physician Wealth Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. O Shaughnessy Asset Management LLC increased its stake in Becton, Dickinson and Company by 53.0% in the third quarter. O Shaughnessy Asset Management LLC now owns 10,566 shares of the medical instruments supplier’s stock valued at $2,732,000 after acquiring an additional 3,661 shares during the last quarter. Synovus Financial Corp grew its stake in shares of Becton, Dickinson and Company by 70.4% during the third quarter. Synovus Financial Corp now owns 7,196 shares of the medical instruments supplier’s stock worth $1,861,000 after buying an additional 2,972 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Becton, Dickinson and Company by 116.3% during the third quarter. Tower Research Capital LLC TRC now owns 10,194 shares of the medical instruments supplier’s stock worth $2,635,000 after buying an additional 5,482 shares during the last quarter. Bank of Nova Scotia grew its stake in shares of Becton, Dickinson and Company by 40.6% during the third quarter. Bank of Nova Scotia now owns 54,217 shares of the medical instruments supplier’s stock worth $14,016,000 after buying an additional 15,662 shares during the last quarter. Finally, Nomura Holdings Inc. grew its stake in shares of Becton, Dickinson and Company by 5.7% during the third quarter. Nomura Holdings Inc. now owns 4,418 shares of the medical instruments supplier’s stock worth $1,142,000 after buying an additional 238 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BDX. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Thursday. Barclays lifted their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $280.17.

Becton, Dickinson and Company Stock Up 1.2 %

Shares of NYSE BDX traded up $2.77 during trading on Friday, hitting $233.71. 2,404,003 shares of the company traded hands, compared to its average volume of 1,471,420. The business’s fifty day moving average is $234.36 and its 200 day moving average is $237.85. Becton, Dickinson and Company has a fifty-two week low of $224.00 and a fifty-two week high of $287.32. The firm has a market capitalization of $67.54 billion, a price-to-earnings ratio of 51.48, a P/E/G ratio of 2.05 and a beta of 0.44. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the business earned $2.86 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities research analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.63%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insiders Place Their Bets

In related news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the sale, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the sale, the executive vice president now directly owns 11,308 shares in the company, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Insiders have sold 8,615 shares of company stock valued at $2,033,381 in the last three months. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.